SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS

The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of...

Full description

Saved in:
Bibliographic Details
Main Authors Nicolas DESROY, Andrew BOGDAN, Robert J. ALTENBACH, Gregory A. GFESSER, Stephen N. GRESZLER, Xueqing WANG, Gang ZHAO, John R. KOENIG, Marc J. SCANIO, Xenia SEARLE, Bo LIU, Philip R. KYM, Ming C. YEUNG
Format Patent
LanguageEnglish
Spanish
Published 12.11.2019
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention. La invención desvela compuestos de formula (I) Ver formula: En donde R1, R2, R2A, R3, R3A, R4 Y R5 son tal como se definen en el presente documento. La presente invención se refiere a compuestos y su uso en el tratamiento de la fibrosis quística, métodos para su producción, composiciones farmacéuticas que los contienen y métodos de tratamiento de la fibrosis quística administrando un compuesto de la invención.
Bibliography:Application Number: MX20190004019